Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Buy Rating Justified: Mirum Pharmaceuticals' Growth Prospects and Market Expansion Post-Livmarli Approval
Mirum Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Mirum Pharmaceuticals on LIVMARLI's EU Approval and Positive Revenue Projections
Mirum Pharmaceuticals Analyst Ratings
JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating
Mirum Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)
Mirum Pharmaceuticals Analyst Ratings
Positive Outlook for Mirum Pharmaceuticals With Buy Rating Amid Upcoming Catalysts and Robust Financials
Mirum Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Natera (NTRA) and Mirum Pharmaceuticals (MIRM)
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)
Mirum Pharmaceuticals Analyst Ratings